First Time Loading...

AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 11 994 GBX -0.27%
Updated: Apr 26, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
AstraZeneca PLC

Revenue
45.8B USD
Cost of Revenue
-8.1B USD
Gross Profit
37.7B USD
Operating Expenses
-28.8B USD
Operating Income
8.9B USD
Other Expenses
-3B USD
Net Income
6B USD

Margins Comparison
AstraZeneca PLC Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
UK
AstraZeneca PLC
LSE:AZN
185.9B GBP
82%
19%
13%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
688.2B USD
79%
30%
15%
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK
85%
45%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY
57%
6%
3%
US
Johnson & Johnson
NYSE:JNJ
353.4B USD
70%
29%
50%
US
Merck & Co Inc
NYSE:MRK
330.9B USD
74%
7%
1%
CH
Novartis AG
SIX:NOVN
183B CHF
74%
27%
32%
CH
Roche Holding AG
SIX:ROG
175.5B CHF
74%
33%
20%
US
Pfizer Inc
NYSE:PFE
142.6B USD
70%
22%
4%
Country UK
Market Cap 185.9B GBP
Gross Margin
82%
Operating Margin
19%
Net Margin
13%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 688.2B USD
Gross Margin
79%
Operating Margin
30%
Net Margin
15%
Country DK
Market Cap 3.9T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
36%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country JP
Market Cap 82T JPY
Gross Margin
57%
Operating Margin
6%
Net Margin
3%
Country US
Market Cap 353.4B USD
Gross Margin
70%
Operating Margin
29%
Net Margin
50%
Country US
Market Cap 330.9B USD
Gross Margin
74%
Operating Margin
7%
Net Margin
1%
Country CH
Market Cap 183B CHF
Gross Margin
74%
Operating Margin
27%
Net Margin
32%
Country CH
Market Cap 175.5B CHF
Gross Margin
74%
Operating Margin
33%
Net Margin
20%
Country US
Market Cap 142.6B USD
Gross Margin
70%
Operating Margin
22%
Net Margin
4%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
AstraZeneca PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
UK
AstraZeneca PLC
LSE:AZN
185.9B GBP
16%
6%
13%
11%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
688.2B USD
49%
9%
30%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK
88%
30%
79%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY
1%
1%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
353.4B USD
56%
23%
18%
14%
US
Merck & Co Inc
NYSE:MRK
330.9B USD
1%
0%
5%
1%
CH
Novartis AG
SIX:NOVN
183B CHF
28%
14%
16%
14%
CH
Roche Holding AG
SIX:ROG
175.5B CHF
40%
13%
30%
23%
US
Pfizer Inc
NYSE:PFE
142.6B USD
2%
1%
8%
14%
Country UK
Market Cap 185.9B GBP
ROE
16%
ROA
6%
ROCE
13%
ROIC
11%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 688.2B USD
ROE
49%
ROA
9%
ROCE
30%
ROIC
16%
Country DK
Market Cap 3.9T DKK
ROE
88%
ROA
30%
ROCE
79%
ROIC
36%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country JP
Market Cap 82T JPY
ROE
1%
ROA
1%
ROCE
2%
ROIC
2%
Country US
Market Cap 353.4B USD
ROE
56%
ROA
23%
ROCE
18%
ROIC
14%
Country US
Market Cap 330.9B USD
ROE
1%
ROA
0%
ROCE
5%
ROIC
1%
Country CH
Market Cap 183B CHF
ROE
28%
ROA
14%
ROCE
16%
ROIC
14%
Country CH
Market Cap 175.5B CHF
ROE
40%
ROA
13%
ROCE
30%
ROIC
23%
Country US
Market Cap 142.6B USD
ROE
2%
ROA
1%
ROCE
8%
ROIC
14%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More